Yimin Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yimin Li has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Qihui Wu
Department of Gynecology, XiangYa Hospital, Central South University, Changsha, China
9 shared publicationsJiaxin Liu
Department of Pathology School of Basic Medical Sciences, Central South University Changsha China
6 shared publications- Chunlin Ou
Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
5 shared publications - Xiaodan Fu
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, China
4 shared publications - Xiaodan Fu
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, China
4 shared publications Yuanyuan Xu
Department of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
4 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published byĀ Springer NatureĀ inĀ Biomarker Research
- Vol.Ā 14 Ā (1) , 143
Dynamic regulation of H3K9 modifications in cancer: pathogenesis and targeted therapies
Post-translational modifications (PTMs) of histone H3 at lysine 9 (H3K9) contribute to chromatin homeostasis and transcriptional regulation and have been i
- 16 October 2026
- Published byĀ Springer NatureĀ inĀ Biomarker Research
- Vol.Ā 14 Ā (1) , 143
Open AccessDynamic regulation of H3K9 modifications in cancer: pathogenesis and targeted therapies
Post-translational modifications (PTMs) of histone H3 at lysine 9 (H3K9) contribute to chromatin homeostasis and transcriptional regulation and have been i
- Open Access
- 7 November 2025
- Published byĀ Springer NatureĀ inĀ Biomarker Research
- Vol.Ā 13 Ā (1) , 1-45
Arginine methylation in cancer: mechanisms and therapeutic implications
Arginine methylation is a critical post-translational modification that modulates protein stability, enzymatic activity, and subcellular localization, thereby shaping cell fate decisions and maintaining cellular homeostasis. As the principal enzymes catalyzing this modification, protein arginine methyltransferases (PRMTs) participate in key biological processes, including transcriptional and post-transcriptional regulation as well as signal transduction. Dysregulated PRMT activity has been increasingly linked to tumor initiation, progression, and therapeutic resistance. This review summarizes PRMT classification, structural and functional characteristics, and upstream regulatory mechanisms, offering a framework for understanding their diverse roles in cancer biology and therapeutic relevance. We further discuss the mechanistic contributions of PRMTs to multiple cancer hallmarks and highlight recent advances in the development of PRMT inhibitors. Finally, we examine current strategies for clinical translation, with particular emphasis on combination approaches involving chemotherapy, targeted therapy, and immunotherapy, thereby offering a foundation for advancing PRMT-targeted precision oncology.
- 7 November 2025
- Published byĀ Springer NatureĀ inĀ Biomarker Research
- Vol.Ā 13 Ā (1) , 1-45
Open AccessArginine methylation in cancer: mechanisms and therapeutic implications
Arginine methylation is a critical post-translational modification that modulates protein stability, enzymatic activity, and subcellular localization, thereby shaping cell fate decisions and maintaining cellular homeostasis. As the principal enzymes catalyzing this modification, protein arginine methyltransferases (PRMTs) participate in key biological processes, including transcriptional and post-transcriptional regulation as well as signal transduction. Dysregulated PRMT activity has been increasingly linked to tumor initiation, progression, and therapeutic resistance. This review summarizes PRMT classification, structural and functional characteristics, and upstream regulatory mechanisms, offering a framework for understanding their diverse roles in cancer biology and therapeutic relevance. We further discuss the mechanistic contributions of PRMTs to multiple cancer hallmarks and highlight recent advances in the development of PRMT inhibitors. Finally, we examine current strategies for clinical translation, with particular emphasis on combination approaches involving chemotherapy, targeted therapy, and immunotherapy, thereby offering a foundation for advancing PRMT-targeted precision oncology.
- Open Access
- 25 July 2025
- Published byĀ Ivyspring International PublisherĀ inĀ Theranostics
- Vol.Ā 15 Ā (16) , 8222-8258
Inhibitory leukocyte immunoglobulin-like receptors, subfamily B (LILRBs) in human diseases: structure, roles, mechanisms, and clinical applications
Leukocyte immunoglobulin-like receptors, subfamily B (LILRBs), are a class of critical immunosuppressive receptors that contribute to immune homeostasis by transmitting suppressive signals upon binding to ligands such as major histocompatibility complex class I molecules. They play key roles in modulating both innate and adaptive immune responses. This review summarizes the structural features, ligand interactions, signaling pathways, and expression regulation of LILRBs, and discusses their roles in immune cell function and disease progression, particularly in the tumor microenvironment. We also review current progress in the development of LILRB-targeted therapies for hematological malignancies and solid tumors and outline the challenges and future directions in translating these findings into clinical applications. By integrating recent advances, this review provides a framework for understanding the potential of LILRBs as therapeutic targets in cancer and immune-related disorders.
- 25 July 2025
- Published byĀ Ivyspring International PublisherĀ inĀ Theranostics
- Vol.Ā 15 Ā (16) , 8222-8258
Open AccessInhibitory leukocyte immunoglobulin-like receptors, subfamily B (LILRBs) in human diseases: structure, roles, mechanisms, and clinical applications
Leukocyte immunoglobulin-like receptors, subfamily B (LILRBs), are a class of critical immunosuppressive receptors that contribute to immune homeostasis by transmitting suppressive signals upon binding to ligands such as major histocompatibility complex class I molecules. They play key roles in modulating both innate and adaptive immune responses. This review summarizes the structural features, ligand interactions, signaling pathways, and expression regulation of LILRBs, and discusses their roles in immune cell function and disease progression, particularly in the tumor microenvironment. We also review current progress in the development of LILRB-targeted therapies for hematological malignancies and solid tumors and outline the challenges and future directions in translating these findings into clinical applications. By integrating recent advances, this review provides a framework for understanding the potential of LILRBs as therapeutic targets in cancer and immune-related disorders.
- Open Access
- 14 July 2025
- Published byĀ WileyĀ inĀ Journal of Cellular and Molecular Medicine
- Vol.Ā 29 Ā (13) , e70721
MultiāOmics Analysis and RealāWorld Data Validation of Serine MetabolismāRelated Genes in Colorectal Cancer
Serine metabolism plays a pivotal role in cancer progression by supporting essential biosynthetic pathways and energy production. Exploring the intricacies of serine metabolism in cancer may uncover novel therapeutic opportunities. This study presents a comprehensive panācancer analysis of serine metabolismārelated genes (SMGs), with a particular emphasis on colorectal cancer (CRC), to elucidate their expression patterns, genetic alterations and clinical significance. We performed a panācancer analysis of SMGs using integrating transcriptomic, genomic and epigenetic data from TCGA and GTEx databases. For CRC, we performed inādepth analyses comparing expression patterns between tumour and normal tissues, examining prognostic significance and exploring associations with the tumour microenvironment (TME). The distribution patterns of SMGs within the TME were further investigated using singleācell RNA sequencing and immunohistochemistry. Key SMGs, including PHGDH, SLC1A5 and SLC38A2, were validated in two independent realāworld cohorts of CRC. Panācancer analysis revealed that SMGs are differentially expressed across tumour types, with their dysregulation associated with copy number alterations and epigenetic modifications. In CRC, aberrant SMG expression is significantly associated with clinical outcomes, key signalling pathways and the TME. Notably, PHGDH was consistently upregulated in CRC and associated with poor prognosis, while SLC1A5 emerged as a potential biomarker for liver metastasis. This study underscores the importance of SMGs, particularly PHGDH, SLC1A5 and SLC38A2, in CRC progression and prognosis. Our findings offer valuable insights into SMGs as a potential therapeutic target and provide a foundation for developing personalised metabolic interventions in CRC.
- 14 July 2025
- Published byĀ WileyĀ inĀ Journal of Cellular and Molecular Medicine
- Vol.Ā 29 Ā (13) , e70721
Open AccessMultiāOmics Analysis and RealāWorld Data Validation of Serine MetabolismāRelated Genes in Colorectal Cancer
Serine metabolism plays a pivotal role in cancer progression by supporting essential biosynthetic pathways and energy production. Exploring the intricacies of serine metabolism in cancer may uncover novel therapeutic opportunities. This study presents a comprehensive panācancer analysis of serine metabolismārelated genes (SMGs), with a particular emphasis on colorectal cancer (CRC), to elucidate their expression patterns, genetic alterations and clinical significance. We performed a panācancer analysis of SMGs using integrating transcriptomic, genomic and epigenetic data from TCGA and GTEx databases. For CRC, we performed inādepth analyses comparing expression patterns between tumour and normal tissues, examining prognostic significance and exploring associations with the tumour microenvironment (TME). The distribution patterns of SMGs within the TME were further investigated using singleācell RNA sequencing and immunohistochemistry. Key SMGs, including PHGDH, SLC1A5 and SLC38A2, were validated in two independent realāworld cohorts of CRC. Panācancer analysis revealed that SMGs are differentially expressed across tumour types, with their dysregulation associated with copy number alterations and epigenetic modifications. In CRC, aberrant SMG expression is significantly associated with clinical outcomes, key signalling pathways and the TME. Notably, PHGDH was consistently upregulated in CRC and associated with poor prognosis, while SLC1A5 emerged as a potential biomarker for liver metastasis. This study underscores the importance of SMGs, particularly PHGDH, SLC1A5 and SLC38A2, in CRC progression and prognosis. Our findings offer valuable insights into SMGs as a potential therapeutic target and provide a foundation for developing personalised metabolic interventions in CRC.
- Open Access
- 30 September 2023
- Published byĀ Springer NatureĀ inĀ Cancer Cell International
- Vol.Ā 23 Ā (1) , 1-16
Integrative evaluation and experimental validation of the immune-modulating potential of dysregulated extracellular matrix genes in high-grade serous ovarian cancer prognosis
Background: High-grade serous ovarian cancer (HGSOC) is a challenging malignancy characterized by complex interactions between tumor cells and the surrounding microenvironment. Understanding the immune landscape of HGSOC, particularly the role of the extracellular matrix (ECM), is crucial for improving prognosis and guiding therapeutic interventions. Methods and results: Using univariate Cox regression analysis, we identified 71 ECM genes associated with prognosis in seven HGSOC populations. The ECMscore signature, consisting of 14 genes, was validated using Cox proportional hazards regression with a lasso penalty. Cox regression analyses demonstrated that ECMscore is an excellent indicator for prognostic classification in prevalent malignancies, including HGSOC. Moreover, patients with higher ECMscores exhibited more active stromal and carcinogenic activation pathways, including apical surface signaling, Notch signaling, apical junctions, Wnt signaling, epithelial-mesenchymal transition, TGF-beta signaling, and angiogenesis. In contrast, patients with relatively low ECMscores showed more active immune-related pathways, such as interferon alpha response, interferon-gamma response, and inflammatory response. The relationship between the ECMscore and genomic anomalies was further examined. Additionally, the correlation between ECMscore and immune microenvironment components and signals in HGSOC was examined in greater detail. Moreover, the expression of MGP, COL8A2, and PAPPA and its correlation with FAP were validated using qRT-PCR on samples from HGSOC. The utility of ECMscore in predicting the prospective clinical success of immunotherapy and its potential in guiding the selection of chemotherapeutic agents were also explored. Similar results were obtained from pan-cancer research. Conclusion: The comprehensive evaluation of the ECM may help identify immune activation and assist patients in HGSOC and even pan-cancer in receiving proper therapy.
- 30 September 2023
- Published byĀ Springer NatureĀ inĀ Cancer Cell International
- Vol.Ā 23 Ā (1) , 1-16
Open AccessIntegrative evaluation and experimental validation of the immune-modulating potential of dysregulated extracellular matrix genes in high-grade serous ovarian cancer prognosis
Background: High-grade serous ovarian cancer (HGSOC) is a challenging malignancy characterized by complex interactions between tumor cells and the surrounding microenvironment. Understanding the immune landscape of HGSOC, particularly the role of the extracellular matrix (ECM), is crucial for improving prognosis and guiding therapeutic interventions. Methods and results: Using univariate Cox regression analysis, we identified 71 ECM genes associated with prognosis in seven HGSOC populations. The ECMscore signature, consisting of 14 genes, was validated using Cox proportional hazards regression with a lasso penalty. Cox regression analyses demonstrated that ECMscore is an excellent indicator for prognostic classification in prevalent malignancies, including HGSOC. Moreover, patients with higher ECMscores exhibited more active stromal and carcinogenic activation pathways, including apical surface signaling, Notch signaling, apical junctions, Wnt signaling, epithelial-mesenchymal transition, TGF-beta signaling, and angiogenesis. In contrast, patients with relatively low ECMscores showed more active immune-related pathways, such as interferon alpha response, interferon-gamma response, and inflammatory response. The relationship between the ECMscore and genomic anomalies was further examined. Additionally, the correlation between ECMscore and immune microenvironment components and signals in HGSOC was examined in greater detail. Moreover, the expression of MGP, COL8A2, and PAPPA and its correlation with FAP were validated using qRT-PCR on samples from HGSOC. The utility of ECMscore in predicting the prospective clinical success of immunotherapy and its potential in guiding the selection of chemotherapeutic agents were also explored. Similar results were obtained from pan-cancer research. Conclusion: The comprehensive evaluation of the ECM may help identify immune activation and assist patients in HGSOC and even pan-cancer in receiving proper therapy.
- Open Access
- 5 April 2023
- Published byĀ Frontiers Media SAĀ inĀ Frontiers in Immunology
- Vol.Ā 14
Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies
Background: High-grade serous ovarian cancer (HGSOC) is a highly lethal gynecological cancer that requires accurate prognostic models and personalized treatment strategies. The tumor microenvironment (TME) is crucial for disease progression and treatment. Machine learning-based integration is a powerful tool for identifying predictive biomarkers and developing prognostic models. Hence, an immune-related risk model developed using machine learning-based integration could improve prognostic prediction and guide personalized treatment for HGSOC.Methods: During the bioinformatic study in HGSOC, we performed (i) consensus clustering to identify immune subtypes based on signatures of immune and stromal cells, (ii) differentially expressed genes and univariate Cox regression analysis to derive TME- and prognosis-related genes, (iii) machine learning-based procedures constructed by ten independent machine learning algorithms to screen and construct a TME-related risk score (TMErisk), and (iv) evaluation of the effect of TMErisk on the deconstruction of TME, indication of genomic instability, and guidance of immunotherapy and chemotherapy.Results: We identified two different immune microenvironment phenotypes and a robust and clinically practicable prognostic scoring system. TMErisk demonstrated superior performance over most clinical features and other published signatures in predicting HGSOC prognosis across cohorts. The low TMErisk group with a notably favorable prognosis was characterized by BRCA1 mutation, activation of immunity, and a better immune response. Conversely, the high TMErisk group was significantly associated with C-X-C motif chemokine ligands deletion and carcinogenic activation pathways. Additionally, low TMErisk group patients were more responsive to eleven candidate agents.Conclusion: Our study developed a novel immune-related risk model that predicts the prognosis of ovarian cancer patients using machine learning-based integration. Additionally, the study not only depicts the diversity of cell components in the TME of HGSOC but also guides the development of potential therapeutic techniques for addressing tumor immunosuppression and enhancing the response to cancer therapy.
- 5 April 2023
- Published byĀ Frontiers Media SAĀ inĀ Frontiers in Immunology
- Vol.Ā 14
Open AccessMachine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies
Background: High-grade serous ovarian cancer (HGSOC) is a highly lethal gynecological cancer that requires accurate prognostic models and personalized treatment strategies. The tumor microenvironment (TME) is crucial for disease progression and treatment. Machine learning-based integration is a powerful tool for identifying predictive biomarkers and developing prognostic models. Hence, an immune-related risk model developed using machine learning-based integration could improve prognostic prediction and guide personalized treatment for HGSOC.Methods: During the bioinformatic study in HGSOC, we performed (i) consensus clustering to identify immune subtypes based on signatures of immune and stromal cells, (ii) differentially expressed genes and univariate Cox regression analysis to derive TME- and prognosis-related genes, (iii) machine learning-based procedures constructed by ten independent machine learning algorithms to screen and construct a TME-related risk score (TMErisk), and (iv) evaluation of the effect of TMErisk on the deconstruction of TME, indication of genomic instability, and guidance of immunotherapy and chemotherapy.Results: We identified two different immune microenvironment phenotypes and a robust and clinically practicable prognostic scoring system. TMErisk demonstrated superior performance over most clinical features and other published signatures in predicting HGSOC prognosis across cohorts. The low TMErisk group with a notably favorable prognosis was characterized by BRCA1 mutation, activation of immunity, and a better immune response. Conversely, the high TMErisk group was significantly associated with C-X-C motif chemokine ligands deletion and carcinogenic activation pathways. Additionally, low TMErisk group patients were more responsive to eleven candidate agents.Conclusion: Our study developed a novel immune-related risk model that predicts the prognosis of ovarian cancer patients using machine learning-based integration. Additionally, the study not only depicts the diversity of cell components in the TME of HGSOC but also guides the development of potential therapeutic techniques for addressing tumor immunosuppression and enhancing the response to cancer therapy.
- Open Access
- 3 March 2023
- Published byĀ Frontiers Media SAĀ inĀ Frontiers in Immunology
- Vol.Ā 14, 1139126
Deciphering comprehensive features of tumor microenvironment controlled by chromatin regulators to predict prognosis and guide therapies in uterine corpus endometrial carcinoma
Background: Dysregulation of chromatin regulators (CRs) can perturb the tumor immune microenvironment, but the underlying mechanism remains unclear. We focused on uterine corpus endometrial carcinoma (UCEC) and used gene expression data from TCGA-UCEC to investigate this mechanism.Methods: We used weighted gene co-expression network analysis (WGCNA) and consensus clustering algorithm to classify UCEC patients into Cluster_L and Cluster_H. TME-associated CRs were identified using WGCNA and differential gene expression analysis. A CR risk score (CRRS) was constructed using univariate Cox and LASSO-Cox regression analyses. A nomogram was developed based on CRRS and clinicopathologic factors to predict patients' prognosis.Results: Lower CRRS was associated with lower grade, more benign molecular subtypes, and improved survival. Patients with low CRRS showed abundant immune infiltration, a higher mutation burden, fewer CNVs, and better response to immunotherapy. Moreover, low CRRS patients were more sensitive to 24 chemotherapeutic agents.Conclusion: A comprehensive assessment of CRRS could identify immune activation and improve the efficacy of UCEC treatments.
- 3 March 2023
- Published byĀ Frontiers Media SAĀ inĀ Frontiers in Immunology
- Vol.Ā 14, 1139126
Open AccessDeciphering comprehensive features of tumor microenvironment controlled by chromatin regulators to predict prognosis and guide therapies in uterine corpus endometrial carcinoma
Background: Dysregulation of chromatin regulators (CRs) can perturb the tumor immune microenvironment, but the underlying mechanism remains unclear. We focused on uterine corpus endometrial carcinoma (UCEC) and used gene expression data from TCGA-UCEC to investigate this mechanism.Methods: We used weighted gene co-expression network analysis (WGCNA) and consensus clustering algorithm to classify UCEC patients into Cluster_L and Cluster_H. TME-associated CRs were identified using WGCNA and differential gene expression analysis. A CR risk score (CRRS) was constructed using univariate Cox and LASSO-Cox regression analyses. A nomogram was developed based on CRRS and clinicopathologic factors to predict patients' prognosis.Results: Lower CRRS was associated with lower grade, more benign molecular subtypes, and improved survival. Patients with low CRRS showed abundant immune infiltration, a higher mutation burden, fewer CNVs, and better response to immunotherapy. Moreover, low CRRS patients were more sensitive to 24 chemotherapeutic agents.Conclusion: A comprehensive assessment of CRRS could identify immune activation and improve the efficacy of UCEC treatments.
- Open Access
- 7 December 2022
- Published byĀ Frontiers Media SAĀ inĀ Frontiers in Molecular Biosciences
- Vol.Ā 9, 1048356
A comprehensive analysis focusing on cuproptosis to investigate its clinical and biological relevance in uterine corpus endometrial carcinoma and its potential in indicating prognosis
Cuproptosis, a novel copper-dependent cell death involving mitochondrial respiration, is distinct from other known death mechanisms, which inspires us to study further in uterine corpus endometrial carcinoma (UCEC). Herein, leveraging comprehensive data from TCGA-UCEC, we conducted transcriptional and genetic analyses of 13 recently identified cuproptosis genes. We discovered severe genetic instability of cuproptosis genes, extensive positive correlations among those genes with each other at the mRNA level, and their involvement in oncogenic pathways in UCEC samples. Next, WGCNA was performed to identify a potential module regulating cuproptosis, in which the hub genes, in addition to 13 cuproptosis genes, were drawn to construct a scoring system termed Cu. Score. Furthermore, its clinical and biological relevance and tumor immune landscape, genetic alterations, as well as predicted sensitivity of chemotherapy drugs in different Cu. Score subgroups had been discussed extensively and in detail. Additionally, univariate Cox and LASSO regression were performed to identify 13 cuproptosis-related prognostic genes to establish a prognostic signature, the Risk. Score. Integrating the Risk. Score and clinical parameters, we established a nomogram with excellent performance to predict the 1-/3-/5-year survival probabilities of UCEC patients. To conclude, we conducted a comprehensive analysis encompassing cuproptosis and developed a cuproptosis scoring system and a prognostic prediction model for UCEC, which may offer help with individualized assessment and treatment for UCEC patients from the perspective of a novel death mechanism.
- 7 December 2022
- Published byĀ Frontiers Media SAĀ inĀ Frontiers in Molecular Biosciences
- Vol.Ā 9, 1048356
Open AccessA comprehensive analysis focusing on cuproptosis to investigate its clinical and biological relevance in uterine corpus endometrial carcinoma and its potential in indicating prognosis
Cuproptosis, a novel copper-dependent cell death involving mitochondrial respiration, is distinct from other known death mechanisms, which inspires us to study further in uterine corpus endometrial carcinoma (UCEC). Herein, leveraging comprehensive data from TCGA-UCEC, we conducted transcriptional and genetic analyses of 13 recently identified cuproptosis genes. We discovered severe genetic instability of cuproptosis genes, extensive positive correlations among those genes with each other at the mRNA level, and their involvement in oncogenic pathways in UCEC samples. Next, WGCNA was performed to identify a potential module regulating cuproptosis, in which the hub genes, in addition to 13 cuproptosis genes, were drawn to construct a scoring system termed Cu. Score. Furthermore, its clinical and biological relevance and tumor immune landscape, genetic alterations, as well as predicted sensitivity of chemotherapy drugs in different Cu. Score subgroups had been discussed extensively and in detail. Additionally, univariate Cox and LASSO regression were performed to identify 13 cuproptosis-related prognostic genes to establish a prognostic signature, the Risk. Score. Integrating the Risk. Score and clinical parameters, we established a nomogram with excellent performance to predict the 1-/3-/5-year survival probabilities of UCEC patients. To conclude, we conducted a comprehensive analysis encompassing cuproptosis and developed a cuproptosis scoring system and a prognostic prediction model for UCEC, which may offer help with individualized assessment and treatment for UCEC patients from the perspective of a novel death mechanism.